Analystreport

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) had its price target lowered by analysts at Chardan Capital from $34.00 to $28.00. They now have a "buy" rating on the

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com